Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab in chronic migraine (HALO CM)
NCT02621931Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of fremanezumab in chronic migraine, sponsored by Teva Pharmaceutical Industries Ltd.. Started Mar 2016; status: completed.
02
Drugs
fremanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT02621931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621931.